Crown Labs Tops Rival Bid In Quest To Buy Biotech Revance

By Al Barbarino · January 17, 2025, 4:20 PM EST

Skincare product company Crown Laboratories Inc. has offered to raise its all-cash bid to buy healthcare biotech company Revance Therapeutics Inc. from $3.10 per share to $3.65 per share as it seeks to...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login